The State of Chronic Kidney Disease, ESRD, and Morbidity and Mortality in the First Year of Dialysis

被引:222
|
作者
Collins, Allan J. [1 ,2 ]
Foley, Robert N. [1 ,2 ]
Gilbertson, David T. [1 ]
Chen, Shu-Chen [1 ]
机构
[1] Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA
[2] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
关键词
D O I
10.2215/CJN.05980809
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This review examines trends in the ESRD program, assessing progress in preventive care, hospitalizations, and mortality since 1989, the year of the Dallas Morbidity and Mortality Conference. The number of prevalent dialysis patients nearly tripled, to 366,000 in 2007 from 123,000 in 1989. Prevalent population mortality rates declined in the mid-1980s but did not change overall through the 1990s; rates declined for patients on dialysis for less than 5 yr but increased for patients on dialysis for longer than 5 yr. Death rates throughout the prevalent population have subsequently declined since 2000. In the incident dialysis population, death rates after the first year have declined, but first-year rates have remained flat since 1996; rates peak in months 2 and 3, then decline to the level of the first month by 1.2 mo. Infectious hospitalization rates in the prevalent population increased 40% in the last 10 yr. For incident patients, infectious hospitalizations increased almost 100% over 10 yr, vascular access hospitalizations by 200%, and cardiovascular hospitalizations by 30%. Use of dialysis catheters is high; 82% of patients start dialysis with a catheter. Poor planning for dialysis initiation may contribute to catheter use and the associated high infectious hospitalization rate, limiting potential for improved patient survival during the first year. Public health programs, including the new Medicare chronic kidney disease education benefit, are needed to promote better care of patients who may need dialysis to reduce the high morbidity and mortality in the first year. Clin J Am Soc Nephrol 4: S5-S11, 2009. doi: 10.2215/CJN.05980809
引用
收藏
页码:S5 / S11
页数:7
相关论文
共 50 条
  • [41] Sevelamer Use and Mortality in People with Chronic Kidney Disease Stages 4 and 5 Not on Dialysis
    Molina, Pablo
    Molina, Mariola D.
    Carrero, Juan J.
    Escudero, Veronica
    Torralba, Javier
    Castro-Alonso, Cristina
    Beltran, Sandra
    Vizcaino, Belen
    Gonzalez-Moya, Mercedes
    Kanter, Julia
    Sancho-Calabuig, Asuncion
    Bover, Jordi
    Gorriz, Jose L.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [42] Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis
    Rhee, Connie M.
    Kovesdy, Csaba P.
    Ravel, Vanessa A.
    Streja, Elani
    Sim, John J.
    You, Amy S.
    Gatwood, Justin
    Amin, Alpesh N.
    Molnar, Miklos Z.
    Nguyen, Danh, V
    Kalantar-Zadeh, Kamyar
    JOURNAL OF RENAL NUTRITION, 2019, 29 (02) : 82 - 90
  • [43] Timing of Dialysis Initiation and Mortality Risk in Chronic Kidney Disease: A Meta-Analysis
    Zhao, Yaya
    Pei, Xiaohua
    Zhao, Weihong
    THERAPEUTIC APHERESIS AND DIALYSIS, 2018, 22 (06) : 600 - 608
  • [44] DOES THE TYPE OF INTERVENTION FOR ISCHAEMIC HEART DISEASE IMPACT ON MORTALITY AND MORBIDITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Jeyaruban, A.
    Hoy, W. E.
    Cameron, A.
    Healy, H. G.
    Zhang, J.
    Mallett, A. J.
    NEPHROLOGY, 2018, 23 : 44 - 44
  • [45] Variability of red blood cell size predicts all-cause mortality, but not progression to dialysis, in patients with chronic kidney disease: A 13-year pre-ESRD registry-based cohort
    Yeh, Hung-Chieh
    Lin, Yu-Ting
    Ting, I-Wen
    Huang, Han-Chun
    Chiang, Hsiu-Yin
    Chung, Chih-Wei
    Chang, Shih-Ni
    Kuo, Chin-Chi
    CLINICA CHIMICA ACTA, 2019, 497 : 163 - 171
  • [46] Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year
    Pierre, Elodie
    Pladys, Adelaide
    Bayat-Makoei, Sahar
    Tattevin, Pierre
    Vigneau, Cecile
    VACCINE, 2023, 41 (24) : 3655 - 3662
  • [47] Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model
    Koukounas, Kalli G.
    Thorsness, Rebecca
    Patzer, Rachel E.
    Wilk, Adam S.
    Drewry, Kelsey M.
    Mehrotra, Rajnish
    Rivera-Hernandez, Maricruz
    Meyers, David J.
    Kim, Daeho
    Trivedi, Amal N.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (02): : 124 - 131
  • [48] Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients: A six year prospective study
    Fellah, Hayet
    Hammami, Mohamed Bassem
    Feki, Moncef
    Boubaker, Karima
    Abdallah, Taleb Ben
    Lacour, Bernard
    Mebazaa, Abderraouf
    Kaabachi, Neziha
    CLINICAL BIOCHEMISTRY, 2009, 42 (7-8) : 648 - 653
  • [49] Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort study
    Kovesdy, CP
    Trivedi, BK
    Anderson, JE
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2006, 13 (02) : 183 - 188
  • [50] Statins for chronic kidney disease not requiring dialysis
    Palmer, Suetonia
    Ruospo, Marinella
    Strippoli, Giovanni F. M.
    NEPHROLOGY, 2015, 20 (04) : 300 - 301